A phase II clinical trial of sorafenib in androgen-independent prostate cancer

Clinical Cancer Research

Volumn 14, Issue 1, 2008, Pages 209-214

  Dahut, William L ^b   Scripture, Charity ^a,b   Posadas, Edwin ^b   Jain, Lokesh ^a,b,e   Gulley, James L ^b   Arlen, Philip M ^b   Wright, John J ^b,d   Yu, Yunkai ^b   Cao, Liang ^b   Steinberg, Seth M ^c   Aragon Ching, Jeanny B ^b   Venitz, Jürgen ^e   Jones, Elizabeth ^c   Chen, Clara C ^c   Figg, William D ^a,b,c,e  

^a Clinical Pharmacology Branch   (United States)

^b Medical Oncology Branch   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Cancer Therapy Evaluation Program   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN; SORAFENIB;

ADULT; AGED; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ATAXIA; BONE METASTASIS; BONE SCINTISCANNING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DESQUAMATION; DIARRHEA; DISEASE COURSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FLATULENCE; GLEASON SCORE; HAND FOOT SYNDROME; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; IN VITRO STUDY; INFECTION; LIVER FUNCTION TEST; MEMORY DISORDER; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; RASH; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT RESPONSE; TUMOR BIOPSY; VOMITING; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; DISEASE-FREE SURVIVAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PYRIDINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 40749122148     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1355     Document Type: Article

References (29)

1. Nexavar® (sorafenib) prescribing information. Bayer Pharmaceuticals Corporation; August 2006.
2. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-44.
3. Yu C, Bruzek LM, Meng XW, et al. The role of Mcl-1 down-regulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005;24:6861-9.
4. Folkman J. The vascularization of tumors. Sci Am 1976;234:58-64, 70-3.
5. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995;36:127-37.
6. Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 1994;73:678-87.
7. Bettencourt MC, Bauer JJ, Sesterhenn IA, Connelly RR, Moul JW. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 1998;160:459-65.
8. Choy M, Rafii S. Role of angiogenesis in the progression and treatment of prostate cancer. Cancer Invest 2001;19:181-91.
9. Sokoloff MH, Chung LW. Targeting angiogenic pathways involving tumor-stromal interaction to treat advanced human prostate cancer. Cancer Metastasis Rev 1998;17:307-15.
10. Clinical trial details for study CALBG9 0401. Baltimore (MD): Greenebaum Cancer Center; 2005.
11. Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22:2532-9.
12. Ning YM, Arlen PM, Gulley JL, et al. A phase II trial of docetaxel, thalidomide, bevacizumab, and prednisone in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). J Clin Oncol 2006;24:13037.
13. Picus J, Halabi S, Rini B, et al. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. In: Proc Am soc Clin Oncol. 2003. p.1578.
14. Erlich S, Tal-Or P, Liebling R, et al. Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells. Biochem Pharmacol 2006;72:427-36.
15. Gioeli D. Signal transduction in prostate cancer progression. Clin Sci Lond 2005;108:293-308.
16. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Jr., Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999;59:279-84.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
18. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-7.
19. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
20. Jain L, Gardner ER, Venitz J, Dahut WL, Figg WD. Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma. J Pharm Biomed Analysis. In press 2008.
21. ATCC CRL-1740 product description. Accessed on May 3. Available from: http://www.atcc.org/common/catalog/numSearch/numResults.cfm?atccNum=CRL-1740.
22. Dixon SC, Kruger EA, Bauer KS, Figg WD. Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells. Cancer Chemother Pharmacol 1999;43 Suppl:S78-84.
23. Dahut WPE, Scripture C, Gulley J, et al. A phase II study of BAY 43-9006 (sorafenib) in patients with androgen-independent prostate cancer (AIPC). Eur J Cancer Suppl 2005;3:248.
24. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:5472-80.
25. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. JClin Oncol 2005;23:965-72.
26. Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688-94.
27. Dahut W, Scripture C, Posadas E, et al. Bony metastatic disease responses to sorafenib (BAY 43-9006) independent of PSA in patients with metastatic androgen independent prostate cancer. J Clin Oncol 2006;24:Abstract 4506.
28. Dixon SC, Knopf KB, Figg WD. The control of prostate-specific antigen expression and gene regulation by pharmacological agents. Pharmacol Rev 2001;53:73-91.
29. Hayashi C, Rittling S, Hayata T, et al. Serum osteopontin, an enhancer of tumor metastasis to bone, promotes B16 melanoma cell migration. J Cell Biochem 2007;101:979-86.